Inicio
Autor Kenny Mauricio Gálvez Cárdenas
|
Comentario :
Médico Internista Hematólogo, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (49)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaCharacteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study / Kenny Mauricio Gálvez Cárdenas ; Laura María Díaz Correa ; Sossa Melo, Claudia ; Abello Polo, Virginia ; Salazar, Luis A. ; Peña, Angela M ; González, María Luna ; Cuervo Lozada, Diana ; Quintero Vega, Guillermo E ; Daza, Jorge ; Omaña Orduz, Olga Paola ; Mantilla, William ; Perdomo, Iván ; Guerrero Burbano, Paola Andrea ; Herrera, Juan Manuel ; Idrobo, Henry ; Rodríguez Veiga, Rebeca ; Correa Correa, Mario Ernesto ; Lobatón, José ; Bermúdez, Carlos Daniel ; Pedraza Morales, Julian Eduardo ; Serrano Casas, Juan Carlos ; Jaramillo, Francisco ; Gómez, Rigoberto ; Rosales, Carmen ; Solano, María Helena ; Varón, Carlos ; Martínez Cuadrón, David ; Montesinos, Pau
Título : Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Laura María Díaz Correa, Autor ; Sossa Melo, Claudia, Autor ; Abello Polo, Virginia, Autor ; Salazar, Luis A., Autor ; Peña, Angela M, Autor ; González, María Luna, Autor ; Cuervo Lozada, Diana, Autor ; Quintero Vega, Guillermo E, Autor ; Daza, Jorge, Autor ; Omaña Orduz, Olga Paola, Autor ; Mantilla, William, Autor ; Perdomo, Iván, Autor ; Guerrero Burbano, Paola Andrea, Autor ; Herrera, Juan Manuel, Autor ; Idrobo, Henry, Autor ; Rodríguez Veiga, Rebeca, Autor ; Correa Correa, Mario Ernesto, Autor ; Lobatón, José, Autor ; Bermúdez, Carlos Daniel, Autor ; Pedraza Morales, Julian Eduardo, Autor ; Serrano Casas, Juan Carlos, Autor ; Jaramillo, Francisco, Autor ; Gómez, Rigoberto, Autor ; Rosales, Carmen, Autor ; Solano, María Helena, Autor ; Varón, Carlos, Autor ; Martínez Cuadrón, David, Autor ; Montesinos, Pau, Autor Fecha de publicación : 2025 Títulos uniformes : Annals of Hematology Idioma : Inglés (eng) Palabras clave : Acute myeloid leukemia; Elderly patients; Overall survival; Treatment outcomes. Resumen : There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60-98), 55% were men, 61% had an ECOG Mención de responsabilidad : Claudia Sossa-Melo, Virginia Abello-Polo, Luis A Salazar, Angela M Peña, María Luna-González 4, Diana Cuervo-Lozada, Guillermo E Quintero-Vega, Jorge Daza, Olga Paola Omaña-Orduz, William Mantilla, Iván Perdomo, Kenny Galvez, Laura María Díaz-Correa, Paola Andrea Guerrero-Burbano, Juan Manuel Herrera, Henry Idrobo, L M Gaviria, Mario Ernesto Correa-Correa, José Lobatón, Carlos Daniel Bermúdez, Julian Eduardo Pedraza-Morales, Juan Carlos Serrano-Casas, Francisco Jaramillo, Rigoberto Gómez, Carmen Rosales, María Helena Solano, Carlos Varón, Rebeca Rodríguez-Veiga, David Martínez-Cuadrón, Pau Montesinos. Referencia : Ann Hematol . 2025 Jan;104(1):369-381 DOI (Digital Object Identifier) : 10.1007/s00277-024-06120-0 PMID : 39815122 Derechos de uso : CC BY-NC-ND En línea : https://pubmed-ncbi-nlm-nih-gov.consultaremota.upb.edu.co/39815122/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Laura María Díaz Correa, Autor ; Sossa Melo, Claudia, Autor ; Abello Polo, Virginia, Autor ; Salazar, Luis A., Autor ; Peña, Angela M, Autor ; González, María Luna, Autor ; Cuervo Lozada, Diana, Autor ; Quintero Vega, Guillermo E, Autor ; Daza, Jorge, Autor ; Omaña Orduz, Olga Paola, Autor ; Mantilla, William, Autor ; Perdomo, Iván, Autor ; Guerrero Burbano, Paola Andrea, Autor ; Herrera, Juan Manuel, Autor ; Idrobo, Henry, Autor ; Rodríguez Veiga, Rebeca, Autor ; Correa Correa, Mario Ernesto, Autor ; Lobatón, José, Autor ; Bermúdez, Carlos Daniel, Autor ; Pedraza Morales, Julian Eduardo, Autor ; Serrano Casas, Juan Carlos, Autor ; Jaramillo, Francisco, Autor ; Gómez, Rigoberto, Autor ; Rosales, Carmen, Autor ; Solano, María Helena, Autor ; Varón, Carlos, Autor ; Martínez Cuadrón, David, Autor ; Montesinos, Pau, Autor . - 2025.
Obra : Annals of Hematology
Idioma : Inglés (eng)
Palabras clave : Acute myeloid leukemia; Elderly patients; Overall survival; Treatment outcomes. Resumen : There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60-98), 55% were men, 61% had an ECOG Mención de responsabilidad : Claudia Sossa-Melo, Virginia Abello-Polo, Luis A Salazar, Angela M Peña, María Luna-González 4, Diana Cuervo-Lozada, Guillermo E Quintero-Vega, Jorge Daza, Olga Paola Omaña-Orduz, William Mantilla, Iván Perdomo, Kenny Galvez, Laura María Díaz-Correa, Paola Andrea Guerrero-Burbano, Juan Manuel Herrera, Henry Idrobo, L M Gaviria, Mario Ernesto Correa-Correa, José Lobatón, Carlos Daniel Bermúdez, Julian Eduardo Pedraza-Morales, Juan Carlos Serrano-Casas, Francisco Jaramillo, Rigoberto Gómez, Carmen Rosales, María Helena Solano, Carlos Varón, Rebeca Rodríguez-Veiga, David Martínez-Cuadrón, Pau Montesinos. Referencia : Ann Hematol . 2025 Jan;104(1):369-381 DOI (Digital Object Identifier) : 10.1007/s00277-024-06120-0 PMID : 39815122 Derechos de uso : CC BY-NC-ND En línea : https://pubmed-ncbi-nlm-nih-gov.consultaremota.upb.edu.co/39815122/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002333 AC-2025-016 Archivo digital Producción Científica Artículos científicos Disponible
Título : Healthcare Systems as Determinants of Outcomes in Multiple Myeloma: Final Results from the Latin American MYLACRE Study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Hungria, Vania, Autor ; Gaiolla, Rafael, Autor ; Remaggi, Guillermina, Autor ; Schutz, Natalia, Autor ; Bittencourt, Rosane, Autor ; Maiolino, Angelo, Autor ; Quintero Vega, Guillermo E, Autor ; Silvana Cugliari, Maria, Autor ; Tobias Braga, Walter Moises, Autor ; Colaco Villarim, Carolina, Autor ; Crusoe, Edvan, Autor ; Enrico, Alicia Ines, Autor ; Caiero, Gaston, Autor ; Bigonha, Jandey, Autor ; Lemos Moura, Fernanda, Autor ; Figueroa, Jair, Autor ; Sossa Melo, Claudia Lucia, Autor ; Lombana, Milton, Autor ; Pei, Huiling, Autor ; Fernandez, Mariana, Autor ; Saes, Jaqueline, Autor ; Trufelli, Damila Cristina, Autor Fecha de publicación : 2025 Títulos uniformes : Blood Advances Idioma : Inglés (eng) Resumen : Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past 2 decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents, and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study of patients with MM in 5 Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged ?18 years diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (n = 339) and private (n = 682) institutions. These 2 groups differed in many respects, with patients from the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio, 0.84; 95% confidence interval, 0.67-1.04; P = .109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. Mención de responsabilidad : Vania Hungria, Rafael Gaiolla, Kenny Galvez, Guillermina Remaggi, Natalia Schutz, Rosane Bittencourt, Angelo Maiolino, Guillermo Quintero, Maria Silvana Cugliari, Walter Moises Tobias Braga, Carolina Colaco Villarim, Edvan Crusoe, Alicia Ines Enrico, Gaston Caiero, Jandey Bigonha, Fernanda Lemos Moura, Jair Figueroa, Claudia Lucia Sossa Melo, Milton Lombana, Huiling Pei, Mariana Fernandez, Jaqueline Saes, Damila Cristina Trufelli. Referencia : Blood Advances Volume 9, Issue 6, 25 March 2025, Pages 1293-1302 DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024013838 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S2473952924007146 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Healthcare Systems as Determinants of Outcomes in Multiple Myeloma: Final Results from the Latin American MYLACRE Study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Hungria, Vania, Autor ; Gaiolla, Rafael, Autor ; Remaggi, Guillermina, Autor ; Schutz, Natalia, Autor ; Bittencourt, Rosane, Autor ; Maiolino, Angelo, Autor ; Quintero Vega, Guillermo E, Autor ; Silvana Cugliari, Maria, Autor ; Tobias Braga, Walter Moises, Autor ; Colaco Villarim, Carolina, Autor ; Crusoe, Edvan, Autor ; Enrico, Alicia Ines, Autor ; Caiero, Gaston, Autor ; Bigonha, Jandey, Autor ; Lemos Moura, Fernanda, Autor ; Figueroa, Jair, Autor ; Sossa Melo, Claudia Lucia, Autor ; Lombana, Milton, Autor ; Pei, Huiling, Autor ; Fernandez, Mariana, Autor ; Saes, Jaqueline, Autor ; Trufelli, Damila Cristina, Autor . - 2025.
Obra : Blood Advances
Idioma : Inglés (eng)
Resumen : Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past 2 decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents, and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study of patients with MM in 5 Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged ?18 years diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (n = 339) and private (n = 682) institutions. These 2 groups differed in many respects, with patients from the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio, 0.84; 95% confidence interval, 0.67-1.04; P = .109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. Mención de responsabilidad : Vania Hungria, Rafael Gaiolla, Kenny Galvez, Guillermina Remaggi, Natalia Schutz, Rosane Bittencourt, Angelo Maiolino, Guillermo Quintero, Maria Silvana Cugliari, Walter Moises Tobias Braga, Carolina Colaco Villarim, Edvan Crusoe, Alicia Ines Enrico, Gaston Caiero, Jandey Bigonha, Fernanda Lemos Moura, Jair Figueroa, Claudia Lucia Sossa Melo, Milton Lombana, Huiling Pei, Mariana Fernandez, Jaqueline Saes, Damila Cristina Trufelli. Referencia : Blood Advances Volume 9, Issue 6, 25 March 2025, Pages 1293-1302 DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024013838 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S2473952924007146 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002345 AC-2025-028 Archivo digital Producción Científica Artículos científicos Disponible
Título : Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Munevar, Isabel, Autor ; Idrobo, Henry, Autor ; Armando Mantilla, William, Autor ; Domingo Saavedra Ramírez, Autor Fecha de publicación : 2025 Títulos uniformes : Clinical Lymphoma, Myeloma and Leukemia Idioma : Inglés (eng) Palabras clave : Dasatinib; Imatinib; Nilotinib; RENEHOC registry; Tyrosine kinase inhibitors Resumen : Background: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI efficacy, safety, and healthcare system challenges. Methods: We performed a descriptive analysis of the sociodemographic and clinical characteristics of 994 CML patients from the RENEHOC cohort in Colombia, who were treated over the past 20 years. Trends in first-line TKI use were assessed, and Kaplan-Meier survival curves were used to estimate EFS and OS. The log-rank test was used to compare survival curves between different first-line TKIs. Results: The analysis shows trends in the use of first-line TKIs over a 20-year period in Colombia, where, as in other countries, the use of second-generation TKIs in the first-line setting is gradually increasing. Despite the difficulties of the Colombian healthcare system, the results in terms of OS are excellent regardless of the first-line TKI; however, patients treated with imatinib switched lines significantly more often than those treated with second-generation TKIs (imatinib 58.7%, nilotinib 19.5%, dasatinib 29.3%). The median duration of treatment was significantly shorter with imatinib compared to dasatinib and nilotinib (4.08, 12.75 and not reached, respectively). Intolerance was the most common reason for switching in this cohort of patients. The median observation time for OS was 64.89 months (SD 60.15), with survival rates of 99.4% at 1 year, 97.7% at 3 years and 96.6% at 5 years. Conclusions: The results of this analysis show excellent results in terms of OS for patients with CML treated in Colombia over the last 20 years, despite the difficulties inherent in the health system. Patients treated with first-line imatinib had more frequent line changes. In general, intolerance was the most common reason for switching lines. Despite its retrospective nature, this study allows us to outline how treatment patterns in the country have changed over time. Continued efforts to include more centers and patients in prospective studies are essential to better understand the long-term effects of treatment and to improve adherence to guideline recommendations in clinical practice. © 2024 The Authors Mención de responsabilidad : Abello Polo, Virginia, Sossa, Claudia, Boquimpani, Carla, Salazar, Luis Antonio, Munevar, Isabel, Gómez, Rigoberto, Cuervo, Diana Marcela, Varón Jaimes, Carlos, Reyes, Jheremy, Idrobo, Henry, Omaña, Paola, Daza, Jorge, Pedraza Morales, Julian Eduardo, Agudelo López, Claudia, Quintero-Vega, Guillermo E., Correa Correa, Mario, Herrera, Juan Manuel, Mantilla, William Armando, Serrano, Juan Carlos, Rosales, Carmen, Gálvez Cárdenas, Kenny Mauricio, Bermúdez, Carlos, Saavedra Ramírez, Domingo, Alzate, Mauricio, Lobatón Ramírez, José Fernando Referencia : Clin Lymphoma Myeloma Leuk . 2024 Dec 28:S2152-2650(24)02464-9. DOI (Digital Object Identifier) : 10.1016/j.clml.2024.12.015 PMID : 39863461 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39863461/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Munevar, Isabel, Autor ; Idrobo, Henry, Autor ; Armando Mantilla, William, Autor ; Domingo Saavedra Ramírez, Autor . - 2025.
Obra : Clinical Lymphoma, Myeloma and Leukemia
Idioma : Inglés (eng)
Palabras clave : Dasatinib; Imatinib; Nilotinib; RENEHOC registry; Tyrosine kinase inhibitors Resumen : Background: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI efficacy, safety, and healthcare system challenges. Methods: We performed a descriptive analysis of the sociodemographic and clinical characteristics of 994 CML patients from the RENEHOC cohort in Colombia, who were treated over the past 20 years. Trends in first-line TKI use were assessed, and Kaplan-Meier survival curves were used to estimate EFS and OS. The log-rank test was used to compare survival curves between different first-line TKIs. Results: The analysis shows trends in the use of first-line TKIs over a 20-year period in Colombia, where, as in other countries, the use of second-generation TKIs in the first-line setting is gradually increasing. Despite the difficulties of the Colombian healthcare system, the results in terms of OS are excellent regardless of the first-line TKI; however, patients treated with imatinib switched lines significantly more often than those treated with second-generation TKIs (imatinib 58.7%, nilotinib 19.5%, dasatinib 29.3%). The median duration of treatment was significantly shorter with imatinib compared to dasatinib and nilotinib (4.08, 12.75 and not reached, respectively). Intolerance was the most common reason for switching in this cohort of patients. The median observation time for OS was 64.89 months (SD 60.15), with survival rates of 99.4% at 1 year, 97.7% at 3 years and 96.6% at 5 years. Conclusions: The results of this analysis show excellent results in terms of OS for patients with CML treated in Colombia over the last 20 years, despite the difficulties inherent in the health system. Patients treated with first-line imatinib had more frequent line changes. In general, intolerance was the most common reason for switching lines. Despite its retrospective nature, this study allows us to outline how treatment patterns in the country have changed over time. Continued efforts to include more centers and patients in prospective studies are essential to better understand the long-term effects of treatment and to improve adherence to guideline recommendations in clinical practice. © 2024 The Authors Mención de responsabilidad : Abello Polo, Virginia, Sossa, Claudia, Boquimpani, Carla, Salazar, Luis Antonio, Munevar, Isabel, Gómez, Rigoberto, Cuervo, Diana Marcela, Varón Jaimes, Carlos, Reyes, Jheremy, Idrobo, Henry, Omaña, Paola, Daza, Jorge, Pedraza Morales, Julian Eduardo, Agudelo López, Claudia, Quintero-Vega, Guillermo E., Correa Correa, Mario, Herrera, Juan Manuel, Mantilla, William Armando, Serrano, Juan Carlos, Rosales, Carmen, Gálvez Cárdenas, Kenny Mauricio, Bermúdez, Carlos, Saavedra Ramírez, Domingo, Alzate, Mauricio, Lobatón Ramírez, José Fernando Referencia : Clin Lymphoma Myeloma Leuk . 2024 Dec 28:S2152-2650(24)02464-9. DOI (Digital Object Identifier) : 10.1016/j.clml.2024.12.015 PMID : 39863461 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39863461/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002322 AC-2025-005 Archivo digital Producción Científica Artículos científicos Disponible 
Título : Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Gupta, Vikas, Autor ; Tomuleasa, Ciprian, Autor ; Barranco Lampón, Gilberto Israel, Autor ; Hou, Hsin-An, Autor ; Helbig, Grzegorz, Autor ; Vachhani, Pankit, Autor ; Symeonidis, Argiris, Autor ; Haznedaroglu, Ibrahim, Autor ; Tatsch, Fernando, Autor ; Chopra, Avijeet S., Autor ; Zhang, Meng, Autor ; Vizkelety, Tamas, Autor ; Murray, Bryan, Autor ; Ross, David M., Autor Fecha de publicación : 2025 Títulos uniformes : Blood Advances Idioma : Inglés (eng) Resumen : Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are not well understood. The METER study was a multi-country, retrospective chart review of MF treatment patterns, treatment effectiveness, and health care resource utilization. Of 997 eligible patients, 65.9% had primary MF, and 11.7% were transfusion dependent. Median time from diagnosis to the start of initial treatment (index date) was 29 days (interquartile range [IQR], 1-140). RUX was the most common first-line (1L) therapy (49.0%), followed by HU (40.2%); 48.5% of patients remained on 1L therapy through week 156. Seventy-seven patients underwent allogeneic stem cell transplantation; transplantation was uncommon at 1L, increasing from 2.2% at week 24 to 11.0% at week 156 in patients ?70 years of age. Median overall survival was 79.1 months (95% confidence interval [95% CI], 70.8 to not estimable [NE]) in all patients, 142.3 months (95% CI, 74.1 to NE) for non-RUX patients, 77.6 months (95% CI, 64.2-85.9) for patients on RUX 1L therapy, and 72.6 months (95% CI, 62.0 to NE) for RUX 2L+ patients. Of patients who experienced ?1 corresponding event, the median hospital length of stay (LoS; n = 520), intensive care unit LoS (n = 71), and number of transfusions (n = 375) were 16 days (IQR, 7-37), 5 days (IQR, 2-13), and 12 (IQR, 4-26), respectively. Despite improvements, there were numerous hospitalization and transfusion events among these patients in routine practice. This trial was registered at www.ClinicalTrials.gov as #NCT05444972. Mención de responsabilidad : Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, Hsin-An Hou, Grzegorz Helbig, Pankit Vachhani, Argiris Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S. Chopra, Meng Zhang, Tamas Vizkelety, Bryan Murray, David M. Ross Referencia : Blood Adv . 2025 Mar 11;9(5):1105-1116. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024014625. PMID : 39729499 Derechos de uso : CC BY-NC-ND En línea : https://ashpublications.org/bloodadvances/article/9/5/1105/534845/Real-world-tre [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Gupta, Vikas, Autor ; Tomuleasa, Ciprian, Autor ; Barranco Lampón, Gilberto Israel, Autor ; Hou, Hsin-An, Autor ; Helbig, Grzegorz, Autor ; Vachhani, Pankit, Autor ; Symeonidis, Argiris, Autor ; Haznedaroglu, Ibrahim, Autor ; Tatsch, Fernando, Autor ; Chopra, Avijeet S., Autor ; Zhang, Meng, Autor ; Vizkelety, Tamas, Autor ; Murray, Bryan, Autor ; Ross, David M., Autor . - 2025.
Obra : Blood Advances
Idioma : Inglés (eng)
Resumen : Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are not well understood. The METER study was a multi-country, retrospective chart review of MF treatment patterns, treatment effectiveness, and health care resource utilization. Of 997 eligible patients, 65.9% had primary MF, and 11.7% were transfusion dependent. Median time from diagnosis to the start of initial treatment (index date) was 29 days (interquartile range [IQR], 1-140). RUX was the most common first-line (1L) therapy (49.0%), followed by HU (40.2%); 48.5% of patients remained on 1L therapy through week 156. Seventy-seven patients underwent allogeneic stem cell transplantation; transplantation was uncommon at 1L, increasing from 2.2% at week 24 to 11.0% at week 156 in patients ?70 years of age. Median overall survival was 79.1 months (95% confidence interval [95% CI], 70.8 to not estimable [NE]) in all patients, 142.3 months (95% CI, 74.1 to NE) for non-RUX patients, 77.6 months (95% CI, 64.2-85.9) for patients on RUX 1L therapy, and 72.6 months (95% CI, 62.0 to NE) for RUX 2L+ patients. Of patients who experienced ?1 corresponding event, the median hospital length of stay (LoS; n = 520), intensive care unit LoS (n = 71), and number of transfusions (n = 375) were 16 days (IQR, 7-37), 5 days (IQR, 2-13), and 12 (IQR, 4-26), respectively. Despite improvements, there were numerous hospitalization and transfusion events among these patients in routine practice. This trial was registered at www.ClinicalTrials.gov as #NCT05444972. Mención de responsabilidad : Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, Hsin-An Hou, Grzegorz Helbig, Pankit Vachhani, Argiris Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S. Chopra, Meng Zhang, Tamas Vizkelety, Bryan Murray, David M. Ross Referencia : Blood Adv . 2025 Mar 11;9(5):1105-1116. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024014625. PMID : 39729499 Derechos de uso : CC BY-NC-ND En línea : https://ashpublications.org/bloodadvances/article/9/5/1105/534845/Real-world-tre [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002339 AC-2025-022 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER studyURL
Título : Registro colombiano de clínicas de anticoagulación (RECCANT) y el uso de agentes reversores (RECCANT-AR): justificación y diseño Otros títulos : Colombian registry of anticoagulation clinics (RECCANT) and the use of reversal agents (RECCANT-AR): rationale and design Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Seni Molina, Sebastián, Autor ; Mora, Arturo D., Autor ; Gutiérrez Posso, Juliana, Autor ; Ñáñez, Maribel, Autor ; Victoria Salcedo, Juan D., Autor ; Díez Sepúlveda, Julio, Autor ; Molina, Dora I., Autor ; Montenegro, Ana C., Autor ; Castillo, Gilberto A., Autor ; Sánchez, Róbinson, Autor ; León Giraldo, Hoover O., Autor ; Gómez Mesa, Juan E., Autor Fecha de publicación : 2025 Títulos uniformes : Revista Colombiana de Cardiología Idioma : Español (spa) Palabras clave : Colombia; Anticoagulación; Agentes reversores; Registros clínicos Resumen : Introducción: La anticoagulación es esencial para tratar enfermedades tromboembólicas y prevenir complicaciones asociadas a patologías como la fibrilación auricular. No obstante, conlleva un riesgo significativo de sangrado, lo que destaca la importancia del uso de agentes reversores. En Colombia la evidencia científica sobre estas terapias es limitada. Objetivo: Implementar el Registro Colombiano de Clínicas de Anticoagulación (RECCANT) y el Registro Colombiano de Clínicas de Anticoagulación y el uso de Agentes Reversores (RECCANT-AR), los cuales buscan llenar esta brecha de información proporcionando datos robustos y representativos sobre estos pacientes. Método: RECCANT es un estudio observacional, analítico, prospectivo y multicéntrico que incluye pacientes mayores de 18 años con indicación de manejo anticoagulante por al menos tres meses. RECCANT-AR es un estudio observacional, analítico, ambispectivo y multicéntrico que incluye pacientes mayores de 18 años que requieren agentes reversores por sangrado relevante o por necesidad de procedimientos invasivos urgentes o prioritarios. Se recopilan datos sociodemográficos, clínicos y terapéuticos utilizando la plataforma electrónica REDCap (Research Electronic Data Capture) para garantizar la seguridad y confidencialidad de la información. Resultados: RECCANT y RECCANT-AR se establecen como los primeros registros nacionales enfocados en caracterizar a pacientes anticoagulados y aquellos con requerimiento de agentes reversores. Conclusiones: RECCANT y RECCANT-AR son esenciales para abordar la brecha de conocimiento sobre anticoagulación y el uso de agentes reversores en Colombia. Al proporcionar información precisa y detallada, estos registros mejorarán la comprensión de los perfiles de los pacientes, identificarán patrones nacionales y apoyarán el desarrollo de estrategias estandarizadas para mejorar la atención y los resultados clínicos en el país. Mención de responsabilidad : Sebastián Seni Molina; Arturo D. Mora; Juliana Gutiérrez-Posso; Maribel Ñáñez; Juan D. Victoria Salcedo; Julio Díez-Sepúlveda; Dora I. Molina; Ana C. Montenegro; Kenny M. Gálvez; Gilberto A. Castillo; Róbinson Sánchez; Hoover O. León-Giraldo; Juan E. Gómez-Mesa Referencia : Rev Colomb Cardiol. 2024;31(6):379-388 DOI (Digital Object Identifier) : 10.24875/RCCAR.24000104 Derechos de uso : CC BY-NC-ND En línea : https://dialnet.unirioja.es/servlet/articulo?codigo=10113613# Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Registro colombiano de clínicas de anticoagulación (RECCANT) y el uso de agentes reversores (RECCANT-AR): justificación y diseño = Colombian registry of anticoagulation clinics (RECCANT) and the use of reversal agents (RECCANT-AR): rationale and design [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Seni Molina, Sebastián, Autor ; Mora, Arturo D., Autor ; Gutiérrez Posso, Juliana, Autor ; Ñáñez, Maribel, Autor ; Victoria Salcedo, Juan D., Autor ; Díez Sepúlveda, Julio, Autor ; Molina, Dora I., Autor ; Montenegro, Ana C., Autor ; Castillo, Gilberto A., Autor ; Sánchez, Róbinson, Autor ; León Giraldo, Hoover O., Autor ; Gómez Mesa, Juan E., Autor . - 2025.
Obra : Revista Colombiana de Cardiología
Idioma : Español (spa)
Palabras clave : Colombia; Anticoagulación; Agentes reversores; Registros clínicos Resumen : Introducción: La anticoagulación es esencial para tratar enfermedades tromboembólicas y prevenir complicaciones asociadas a patologías como la fibrilación auricular. No obstante, conlleva un riesgo significativo de sangrado, lo que destaca la importancia del uso de agentes reversores. En Colombia la evidencia científica sobre estas terapias es limitada. Objetivo: Implementar el Registro Colombiano de Clínicas de Anticoagulación (RECCANT) y el Registro Colombiano de Clínicas de Anticoagulación y el uso de Agentes Reversores (RECCANT-AR), los cuales buscan llenar esta brecha de información proporcionando datos robustos y representativos sobre estos pacientes. Método: RECCANT es un estudio observacional, analítico, prospectivo y multicéntrico que incluye pacientes mayores de 18 años con indicación de manejo anticoagulante por al menos tres meses. RECCANT-AR es un estudio observacional, analítico, ambispectivo y multicéntrico que incluye pacientes mayores de 18 años que requieren agentes reversores por sangrado relevante o por necesidad de procedimientos invasivos urgentes o prioritarios. Se recopilan datos sociodemográficos, clínicos y terapéuticos utilizando la plataforma electrónica REDCap (Research Electronic Data Capture) para garantizar la seguridad y confidencialidad de la información. Resultados: RECCANT y RECCANT-AR se establecen como los primeros registros nacionales enfocados en caracterizar a pacientes anticoagulados y aquellos con requerimiento de agentes reversores. Conclusiones: RECCANT y RECCANT-AR son esenciales para abordar la brecha de conocimiento sobre anticoagulación y el uso de agentes reversores en Colombia. Al proporcionar información precisa y detallada, estos registros mejorarán la comprensión de los perfiles de los pacientes, identificarán patrones nacionales y apoyarán el desarrollo de estrategias estandarizadas para mejorar la atención y los resultados clínicos en el país. Mención de responsabilidad : Sebastián Seni Molina; Arturo D. Mora; Juliana Gutiérrez-Posso; Maribel Ñáñez; Juan D. Victoria Salcedo; Julio Díez-Sepúlveda; Dora I. Molina; Ana C. Montenegro; Kenny M. Gálvez; Gilberto A. Castillo; Róbinson Sánchez; Hoover O. León-Giraldo; Juan E. Gómez-Mesa Referencia : Rev Colomb Cardiol. 2024;31(6):379-388 DOI (Digital Object Identifier) : 10.24875/RCCAR.24000104 Derechos de uso : CC BY-NC-ND En línea : https://dialnet.unirioja.es/servlet/articulo?codigo=10113613# Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002370 AC-2025-053 Archivo digital Producción Científica Artículos científicos Disponible
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
